Top of this page
Skip navigation, go straight to the content
Building the next generation biopharma leader
Discover how we are connecting patients, people and science in new ways to make breakthroughs in severe diseases
A global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of € 3.1 billion in 2009.
Many companies claim to be patient-driven, but for UCB it is a living reality. In fact, we do not think of people with severe diseases as "patients" but as individuals with lives beyond their disease.